Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16908459 | 0.86 | CA1 (0.35) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL16177831 | 0.80 | CA1 (0.46) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL30876263 | 0.80 | CA1 (0.46) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL282282 | 0.80 | CA1 (0.41) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL28282385 | 0.78 | KDM1A (0.34) | CA1CA2CA9CA12CA7 | |
| SCHEMBL19748545 | 0.77 | CA1 (0.43) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL18230947 | 0.76 | PTGS2 (0.41) | CA1CA2CA9HSD17B10 | |
| SCHEMBL7919248 | 0.76 | ALDH1A1 (0.37) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL603928 | 0.76 | CA2 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL121437 | 0.76 | CA2 (0.42) | CA1CA2CA9ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| CN-115745910-B | Chemical compound | 安塔比奥公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2025-03-13 | — | — | US | disclosed |
| CN-118488952-A | Substituted quinoline derivatives | 安斯泰来制药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12018001-B2 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-06-25 | — | — | US | disclosed |
| CN-113272301-B | Heterocyclic compound, intermediate, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-3802499-B1 | PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-112236416-B | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | 科赛普特治疗公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| CN-117069724-A | Fused ring compounds, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006134481-A1 | INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | CA1 2869/4885CA2 3537/4885CA9 4554/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | CA1 2869/4885CA2 3537/4885CA9 4554/4885 |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | CHRNA4, CHRNA2, CHRNA5 | CA1 3670/4885CA2 1558/4885CA9 4483/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | CA1 2869/4885CA2 3537/4885CA9 4554/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | CA1 3146/4885CA2 4218/4885CA9 4538/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | CA1 1419/4885CA2 823/4885CA9 1947/4885 |
| US-12018001-B2 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | CA1 4712/4885CA2 4360/4885CA9 4784/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | CA1 1419/4885CA2 823/4885CA9 1947/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | CA1 3170/4885CA2 2210/4885CA9 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.